Biochemical control of prostate cancer with iodine-125 brachytherapy alone: experience from a single institution

Amadei, Larissa Pereira da Ponte; Silva, João Luis Fernandes; Hanna, Samir Abdallah; Haddad, Cláudio Maluf; Nesrallah, Adriano; Carvalho, Heloísa A.

doi:10.1007/s12094-012-0810-6

Cited by 4 publications

(3 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…It is generally used as a single treatment, with good results in cases of low or intermediate risk. 7 The low energy of these isotopes guarantees social and family life of patients after implantation, almost without restrictions. The great advantage of brachytherapy is the convenience of a oneday treatment that can be performed without the need for hospitalization.…”

mentioning

confidence: 99%

Brachytherapy and radical prostatectomy in patients with early prostate cancer

Ferreira

Guerra

Lopes

et al. 2015

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

Methods: all had prostate-specific antigen, Gleason scores and clinical stage recorded prior to treatment. Biochemical relapse was defined as prostate-specific antigen (PSA)>0.4ng/mL for radical prostatectomy, and any elevation equal or higher than 2ng/mL over the PSA nadir for implanted patients. To analyze the effect of treatment on biochemical recurrence-free survival (BRFS), Kaplan-Meier curves and Cox regression were generated. Mean follow-up time was 56.1 months for patients with the implant, and 26.6 months for those operated on. BRFS in 5 years was 69% (95% CI: 58.18-77.45) for the whole cohort. Discussion: when stratified according to treatment, survival of patients who had undergone brachytherapy (79.70%) was higher to those operated on (44.30%; pvalue=0.0056). Upon multivariate analysis, independent predictors were iPSA (HR: 2.91, 95% CI: 1,32-6,42), Gleason score (HR: 2.18, 95% CI: 1,00-4,81) and treatment modality (HR: 2.61, 95% CI: 1.18-5,75). Risk of biochemical failure was higher with surgery than brachytherapy, which may be related to the failure criteria adopted, which is different for each therapy, as well as the high rate of histological progression between preoperative prostate biopsy and surgical specimen. Conclusion: it was found that brachytherapy is a good therapeutic option for low risk prostate cancer.

show abstract

mentioning

confidence: 99%

Brachytherapy and radical prostatectomy in patients with early prostate cancer

Ferreira

Guerra

Lopes

et al. 2015

Rev. Assoc. Med. Bras.

View full text Add to dashboard Cite

show abstract

“…It is well know that an adequate prostate coverage with the prescription dose in the post-implant analysis is related to better BFFS (17). Pereira da Ponte Amadei et al (18) published a retrospective data of first patients treated at the same hospital without post-implant dosimetry, and the BFFS rate was lower (80% of 5-year BFFS).…”

Section: Discussionmentioning

confidence: 99%

Prostate brachytherapy with iodine-125 seeds: analysis of a single institutional cohort

et al. 2019

View full text Add to dashboard Cite

Objectives: Brachytherapy (BT) with iodine-125 seeds placement is a consolidated treatment for prostate cancer. The objective of this study was to assess the clinical outcomes in patients with prostate cancer who underwent low-dose-rate (LDR) -BT alone in a single Brazilian institution. Materials and Methods: Patients treated with iodine-125 BT were retrospectively assessed after at least 5 years of follow-up. Patients who received combination therapy (External beam radiation therapy-EBRT and BT) and salvage BT were not included. Results: 406 men were included in the study (65.5% low-risk, 30% intermediate-risk, and 4.5% high-risk patients). After a median follow-up of 87.5 months, 61 (15.0%) patients developed biochemical recurrence. The actuarial biochemical failure-free survival (BFFS) at 5 and 10 years were 90.6% and 82.2%, respectively. A PSA nadir ≥ 1 ng / mL was associated with a higher risk of biochemical failure (HR = 5.81; 95% CI: 3.39 to 9.94; p ≤ 0.001). The actuarial metastasis-free survival (MFS) at 5 and 10 years were 98.3% and 94%, respectively. The actuarial overall survival (OS) at 5 and 10 years were 96.2% and 85.1%, respectively. Acute and late grade 2 and 3 gastrointestinal toxicities were observed in 5.6%, 0.5%, 4.6% and 0.5% of cases, respectively. For genitourinary the observed acute and late grade 2 and 3 toxicities rates were 57.3%, 3.6%, 28% and 3.1%, respectively. No grade 4 and 5 were observed. Conclusions: BT was effective as a definitive treatment modality for prostate cancer, and its endpoints and toxicities were comparable to those of the main series in the literature.

show abstract

“…[16], 5-летняя выживаемость без биохимического рецидива наблюдалась в 94,1% по критериям ASTRO. Пациентам группы промежуточного риска может быть назначена также низкодозная брахитерапия в сочетании с ДЛТ (40-50 Гр) и с 4-6-месячным курсом неоадъювантной/интер-куррентной/адъювантной антиандрогенной терапии или без нее [17]. Пациентам группы высокого риска может быть рекомендо-вана сочетанная лучевая терапия: ДЛТ (40-50 Гр) и низкодозная брахитерапия с добавлением от 2 до 3 лет неоадъювантной/адъю-вантной антиандрогенной терапии или без нее [18].…”

Section: брахитерапияunclassified